Anebulo Pharmaceuticals (ANEB) Profit After Tax (2020 - 2025)

Anebulo Pharmaceuticals (ANEB) has reported Profit After Tax for 6 consecutive years, with -$2.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Profit After Tax rose 18.82% year-over-year to -$2.0 million; the TTM figure through Dec 2025 stood at -$8.0 million (down 4.78% YoY), while the FY2025 annual figure was -$8.5 million, down 3.64% from the prior year.
• Profit After Tax climbed to -$2.0 million in Q4 2025 per ANEB's latest filing, from -$2.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$555832.0 in Q1 2021 and bottomed at -$29.1 million in Q2 2021.
• Historically, Profit After Tax has averaged -$3.5 million across 5 years, with a median of -$2.2 million in 2024.
• Annual changes were most pronounced in 2021 — Profit After Tax tumbled 505.9% — and 2022, when it surged 92.02%.
• Anebulo Pharmaceuticals' Profit After Tax stood at -$1.1 million in 2021, then plunged by 256.66% to -$3.8 million in 2022, then increased by 28.99% to -$2.7 million in 2023, then grew by 9.36% to -$2.5 million in 2024, then gained by 18.82% to -$2.0 million in 2025.
• Business Quant data shows ANEB's Profit After Tax at -$2.0 million in Q4 2025, -$2.2 million in Q3 2025, and -$2.2 million in Q2 2025.